Editorial Board About Us

Prostatitis

All articles from this key word are listed below.

Volume 2, Number 3 Meeting Reviews

Special Report on Prostatitis Initiatives and Future Research

Second International Prostatitis Collaborative Network Meeting

J Curtis Nickel

Prostatitis Epidemiology Etiology Antibiotic therapy Physical therapy

Volume 3, Number 1 Meeting Reviews

International Symposium on UTI Management

Advances in Urinary Tract Infection Management

J Curtis Nickel

Pyelonephritis Cystitis Prostatitis Urinary tract infection (UTI)

Volume 4, Number 4 Review Articles

The Picture of the Prostatic Lymphokine Network Is Becoming Increasingly Complex

Georg E Steiner Gero Kramer Martin Newman Chung Lee Alessandra Handisurya Michael Marberger Bob Djavan

BPH Prostatitis Leukocyte Pro-inflammatory cytokine Interleukin Interferon-

Volume 4, Supplement 1 Supplement

Interstitial Cystitis--Epidemiology, Diagnostic Criteria, Clinical Markers

Interstitial cystitis Prostatitis Glomerulations Clinical markers

Volume 4, Supplement 1 Supplement

Interstitial Cystitis and Lower Urinary Tract Symptoms in Males and Females--The Combined Role of Potassium and Epithelial Dysfunction

C Lowell Parsons

Interstitial cystitis Bladder Prostatitis Potassium sensitivity test Epithelial dysfunction Pelvic pain Dyspareunia

Volume 7, Number 4 Meeting Reviews

Best of the SIU Meeting on Prostatic Disease

Meeting Review

J Curtis Nickel

Prostate cancer Lower urinary tract symptoms Prostate-specific antigen Erectile dysfunction Prostatitis Benign prostatichyperplasia Prostate Cancer Prevention Trial

Volume 8, Number 1 Meeting Reviews

Changing Paradigms for Chronic Pelvic Pain

Meeting Review

Richard Berger Michel Pontari J Curtis Nickel

A Report from the Chronic Pelvic Pain/Chronic Prostatitis Scientific Workshop October 19-21, 2005 Baltimore, MD

Interstitial cystitis Chronic pelvic pain syndrome Prostatitis Pain Psychosocial aspects of pain Alternative treatments Biopsychosocial treatment model

Volume 10, Number 3 Review Articles

Nutraceuticals in Prostate Disease: The Urologist’s Role

Treatment Update

Mark A Moyad Daniel Shoskes Claus G Roehrborn J Curtis Nickel

Interest in and use of complementary and alternative therapies, especially nutraceuticals, is high in prostate disease. These therapies have shown potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer. Some have produced results equal to or better than pharmaceuticals currently prescribed for BPH. In category III prostatitis, some nutraceuticals may offer relief to patients who get little from standard therapy. Because it is becoming apparent that inflammation may play a role in the progression of BPH and development of prostate cancer, nutraceuticals, which commonly have anti-inflammatory properties, may play a role. These therapies have also shown potential in prostate cancer treatment and prevention, especially those that also reduce cardiovascular events or risk. Nevertheless, uses of some nutraceuticals in prostate disease have had less desirable consequences, showing lack of efficacy, adulteration, and/or severe side effects or drug interactions. By ensuring that these therapies undergo careful study for effectiveness, quality, and safety, urologists can look forward to adding them to their evidence-based armamentarium for prostate disease. [Rev Urol. 2008;10(3):192-206]

Prostate cancer Benign prostatic hyperplasia Prostatitis Complementary or alternative medical therapy Nutraceuticals

Volume 10, Number 3 Review Articles

Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice

Diagnostic Update

Leonard S Marks David G Bostwick

A specific marker for early prostate cancer would fill an important void. In initial evaluations of the prostate cancer antigen 3 (PCA3) gene vis-à-vis serum prostate-specific antigen (PSA) levels, the gene offers great promise. At the cellular level, PCA3 specificity for cancer is nearly perfect because of the gross overexpression of the gene by cancer cells. As a clinical test for early prostate cancer, heightened specificity is also seen in urine containing prostate cells from men with the disease. PCA3 gene testing holds valuable potential in PSA quandary situations: (1) men with elevated PSA levels but no cancer on initial biopsy; (2) men found to have cancer despite normal levels of PSA; (3) men with PSA elevations associated with varying degrees of prostatitis; and (4) men undergoing active surveillance for presumed microfocal disease. [Rev Urol. 2008;10(3):175-181]

Prostate cancer Benign prostatic hyperplasia Prostate-specific antigen Prostatitis Watchful waiting Prostate cancer antigen 3 gene Microfocal disease